<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[board of directors and merck Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/board+of+directors+and+merck.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to board of directors and merck]]></description>
	<s:counts start="0" returned="20" found="23" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Wyeth CEO Got 69% Pay Raise; Was "Required" to Use Helicopter; Plus $24 Million Pfizer Sale Bonus]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001519/wyeth-ceo-got-69-pay-raise-was-required-to-use-a-helicopter-plus-24-million-pfizer-sales-bonus/]]></link>
		<description><![CDATA[Wyeth CEO Bernard Poussot received a 69 percent compensation raise in 2008, to $21.3 million, in addition to a $24 million change-in-control bonus for selling his company to Pfizer.*    Wyeth also took the explanation of executive perks to new levels, saying that Wyeth "requires" Poussot to travel...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 30 Mar 2009 07:56:04 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/compensation.html"><![CDATA[Compensation]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/exec.html"><![CDATA[Exec]]></category>
		<category domain="http://resources.bnet.com/topic/ceo.html"><![CDATA[CEO]]></category>
		<category domain="http://resources.bnet.com/topic/norden.html"><![CDATA[Norden]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/taxes.html"><![CDATA[Taxes]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/financial+planning.html"><![CDATA[Financial Planning]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">PFE,WYE</category>
	</item>
	<item>
		<title><![CDATA[Valeant Executive Pay Doubles to $19.7 Million Despite Quadrupling of Company's Losses]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001505/valeant-executive-pay-doubles-to-197-million-despite-quadrupling-of-companys-losses/]]></link>
		<description><![CDATA[Valeant Pharmaceuticals saw its revenues decline, its net loss quadruple, and its cash sink by $109 million in 2008. But the compensation of its top executives doubled, to $19.7 million in 2008 from $8.6 million in 2007.    Half of that, $9.7 million, went to CEO J. Michael...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 27 Mar 2009 11:09:50 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/compensation.html"><![CDATA[Compensation]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/ceo.html"><![CDATA[CEO]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Shire CEO Compensation Report Successfully Conceals CEO Compensation]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001461/shire-ceo-compensation-report-successfully-conceals-ceo-compensation/]]></link>
		<description><![CDATA[Shire, the British company that markets Adderall and Vyvanse, has produced a compensation report for its senior executives that is all but impossible to understand.    The disclosure, starting on page 52 of the annual report, describes the compensation of just three of its top executives -- former...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 25 Mar 2009 08:05:22 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/compensation.html"><![CDATA[Compensation]]></category>
		<category domain="http://resources.bnet.com/topic/exec.html"><![CDATA[Exec]]></category>
		<category domain="http://resources.bnet.com/topic/ceo.html"><![CDATA[CEO]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/values.html"><![CDATA[Values]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Icahn Moves on Amylin; Will Lilly Step Up?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000777/icahn-moves-on-amylin-will-lilly-step-up/]]></link>
		<description><![CDATA[BNET's 10-Q Detective, David Phillips, reports that Carl Icahn has filed papers to nominate a slate of directors for the board of Amylin, maker of diabetes drug Byetta.    The last time Icahn interfered with a smaller company, ImClone, it ended up being bought by Eli Lilly. Here's...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 30 Jan 2009 12:29:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Applera Corporation F1Q08 (Qtr End 9/30/07) Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14046_23-232503.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Thank you sir. [Operator&#8217;s instructions.]  One moment while we compile a list of questions. Our first question will come from the line of Ross Muken of Deutsche Bank, please proceed.  Ross Muken &#8211; Deutsche Bank  Good morning everyone.  Mark P. Stevenson &#8211;...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 25 Oct 2007 22:00:10 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/applera+corp..html"><![CDATA[Applera Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABI</category>
		<category domain="tickers">ABI</category>
	</item>
	<item>
		<title><![CDATA[K2 Inc. Appoints Richard J. Heckmann as Executive Chairman and J. Wayne Merck as CEO]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Feb_16/ai_n18618422]]></link>
		<description><![CDATA[CARLSBAD, Calif. -- K2 Inc. (NYSE: KTO) announced today that J. Wayne Merck was appointed as the Company's President and Chief Executive Officer, and to K2's Board of Directors. Mr. Merck, a 15-year veteran of K2 Inc. and its predecessor companies, has served as President and Chief Operating Officer since...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 16 Feb 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/k2.html"><![CDATA[K2]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck Board Appoints Special Committee to Review VIOXX Withdrawal]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2004_Dec_7/ai_n8550458]]></link>
		<description><![CDATA[WHITEHOUSE STATION, N.J. -- The Board of Directors of Merck & Co., Inc. announced today that it has appointed a Special Board Committee to review the company's actions prior to Merck's voluntary withdrawal of VIOXX, to act for the Board in responding to shareholder litigation matters related to the withdrawal...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 07 Dec 2004 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/board.html"><![CDATA[board]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Ogilvy & Mather's Shelly Lazarus Elected to Merck Board of Directors]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2004_Oct_6/ai_n6224219]]></link>
		<description><![CDATA[WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. today announced that Shelly Lazarus, 57, chairman and chief executive officer of Ogilvy & Mather Worldwide, one of the world's leading advertising and marketing communication companies, will join the company's Board of Directors effective Oct. 26. With her election, Ms. Lazarus will...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 06 Oct 2004 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/board+of+directors.html"><![CDATA[board of directors]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/ogilvy+%2526+mather.html"><![CDATA[Ogilvy & Mather]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Norwood Abbey Appoints Three USA Based Non-Executive Directors]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2004_Oct_5/ai_n6222811]]></link>
		<description><![CDATA[MELBOURNE, Australia -- Norwood Abbey Ltd. (other-OTC:NABYF) (ASX:NAL):Key Points:      --  Three new USA based directors appointed to Norwood Abbey Board         of Directors         -- Elizabeth Wyatt -- former Vice...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 05 Oct 2004 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/board.html"><![CDATA[board]]></category>
		<category domain="http://resources.bnet.com/topic/director.html"><![CDATA[director]]></category>
		<category domain="http://resources.bnet.com/topic/massachusetts+institute+of+technology.html"><![CDATA[Massachusetts Institute of Technology]]></category>
		<category domain="http://resources.bnet.com/topic/professor.html"><![CDATA[professor]]></category>
		<category domain="http://resources.bnet.com/topic/richard.html"><![CDATA[Richard]]></category>
		<category domain="http://resources.bnet.com/topic/schering-plough+corp..html"><![CDATA[Schering-Plough Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SGP</category>
		<category domain="tickers">SGP</category>
	</item>
	<item>
		<title><![CDATA[Targacept]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5255/is_4/ai_n29073419]]></link>
		<description><![CDATA[Targacept, Winston-Salem, North Carolina, a central nervous system-focused biopharmaceuticals company, has announced the addition of Errol De Souza to its board of directors. De Souza is currently president and CEO of Archemix, a biopharmaceutical company developing aptamer therapeutics, Before joining Archemix, De Souza was president and CEO of Synaptic Pharmaceutical....]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 16 Feb 2004 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/aventis.html"><![CDATA[Aventis]]></category>
		<category domain="http://resources.bnet.com/topic/e.i.+du+pont+de+nemours+%2526+co..html"><![CDATA[E.I. Du Pont de Nemours & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Bennett M. Shapiro. (Jobs and People).(been appointed to the board of directors of Elixir Pharmaceuticals Inc.)(Brief Article)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb4250/is_200304/ai_n13360656]]></link>
		<description><![CDATA[Bennett M. Shapiro has been appointed to the board of directors of  Elixir Pharmaceuticals Inc. Dr. Shapiro is currently executive vice  president of worldwide licensing and external research at Merck &  Co. Inc. He has extensive pharmaceutical business and research  experience.  ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 21 Apr 2003 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/elixir+pharmaceuticals+inc..html"><![CDATA[Elixir Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Galt Appoints Former Merck & Co. Senior Vice President Dr. Louis Sherwood to Board of Directors; Sherwood to Help Drive Drug Safety Company's Direction and Growth]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2002_June_17/ai_87386528]]></link>
		<description><![CDATA[Business/Technology Editors & Health/Medical Writers]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 17 Jun 2002 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/board.html"><![CDATA[board]]></category>
		<category domain="http://resources.bnet.com/topic/board+of+directors.html"><![CDATA[board of directors]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck & Co. Inc.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb4250/is_200002/ai_n13203096]]></link>
		<description><![CDATA[MERCK & Co. Inc.'s board of directors has approved a $10  billion treasury stock repurchase. Merck is currently making purchases  under a July 1998, $5 billion authorization, ...    MERCK & Co. Inc.'s board of directors has approved a $10  billion treasury stock repurchase. Merck...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 28 Feb 2000 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/authorization.html"><![CDATA[authorization]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck Announces 2 for 1 Stock Split and Quarterly Dividend]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_1998_Nov_24/ai_53262598]]></link>
		<description><![CDATA[WHITEHOUSE STATION, N.J.--BUSINESS WIRE--Nov. 24, 1998--The Board of Directors of Merck & Co., Inc., meeting today, voted to split the common stock of the Company two for one. The additional shares will be distributed on or about February 16, 1999, to shareholders of record at the close of business on...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 24 Nov 1998 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck Announces Dividend Increase and $5 Billion Share Repurchase Program]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_1998_July_28/ai_50203001]]></link>
		<description><![CDATA[WHITEHOUSE STATION, N.J.--BUSINESS WIRE--July 28, 1998--The Board of Directors of Merck & Co., Inc., in two separate actions, declared a quarterly dividend of 54 cents a share and approved a new $5 billion treasury stock purchase program.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 28 Jul 1998 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Genta Appoints Kenneth G. Kasses as President and CEO]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_1997_Sept_22/ai_19769608]]></link>
		<description><![CDATA[SAN DIEGO--BUSINESS WIRE--Sept. 22, 1997--Genta Incorporated (Nasdaq: GNTA) today announced that its Board of Directors has appointed Kenneth G. Kasses, Ph.D., 52, as President and Chief Executive Officer effective October 1, filling a previous vacancy. He has also been named a director of the Company, bringing total membership of the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 22 Sep 1997 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/director.html"><![CDATA[director]]></category>
		<category domain="http://resources.bnet.com/topic/dr..html"><![CDATA[Dr.]]></category>
		<category domain="http://resources.bnet.com/topic/dupont+co..html"><![CDATA[DuPont Co.]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/president.html"><![CDATA[president]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[Merck announces dividend increase and $5 billion share repurchase program]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_1997_Feb_25/ai_19154925]]></link>
		<description><![CDATA[WHITEHOUSE STATION, N.J.--BUSINESS WIRE--February 25, 1997-- The Board of Directors of Merck & Co., Inc., in two separate actions, declared a quarterly dividend of 42 cents a share and approved a new $5 billion treasury stock purchase program.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 25 Feb 1997 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/dividend.html"><![CDATA[dividend]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Molecular Biosystems appoints Jerry T. Jackson to board of directors]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_1996_Dec_18/ai_18958792]]></link>
		<description><![CDATA[SAN DIEGO--BUSINESS WIRE--Dec. 18, 1996--Molecular Biosystems Inc. (NYSE:MB) MBI Wednesday announced that Jerry T. Jackson, former executive vice president of Merck & Co. Inc., has been appointed to the company's board of directors.    Jackson brings 30 years of worldwide marketing, sales and product launch experience to MBI....]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 18 Dec 1996 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biosystems.html"><![CDATA[Biosystems]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Merck board declares dividend and approves $3 billion treasury stock purchase program]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_1995_Nov_28/ai_17767664]]></link>
		<description><![CDATA[WHITEHOUSE STATION, N.J.--BUSINESS WIRE--Nov. 28, 1995--The Board of Directors of Merck & Co., Inc., in two separate actions today, declared a quarterly dividend of 34 cents a share and approved a new $3 billion treasury stock purchase program.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 28 Nov 1995 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/board.html"><![CDATA[board]]></category>
		<category domain="http://resources.bnet.com/topic/dividend.html"><![CDATA[dividend]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Champion International Corporation Elects Lawrence A. Bossidy To Board Of Directors]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_1995_Oct_19/ai_17417070]]></link>
		<description><![CDATA[STAMFORD, CT--BUSINESS WIRE--October 19, 1995--Champion International Corporation today announced that Lawrence A. Bossidy has been elected to the Board of Directors.Mr. Bossidy is Chairman and Chief Executive Officer of AlliedSignal Inc., which he joined in 1991.  From 1957 to 1991, he served in various executive and financial positions, including...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 19 Oct 1995 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/board.html"><![CDATA[board]]></category>
		<category domain="http://resources.bnet.com/topic/business+wire.html"><![CDATA[Business Wire]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
